[1] [1] GAWAKO M, LINZ D. Atrial fibrillation detection and management in hypertension[J]. Hypertension, 2023, 80(3): 523-533.

[2] [2] GLADSTONE D J, WACHTER R, SCHMALSTIEG-BAHR K, et al. Screening for atrial fibrillation in the older population: a randomized clinical trial[J]. JAMA Cardiol, 2021, 6(5): 558-567.

[3] [3] RIDKER P M, RANE M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease[J]. Circ Res, 2021, 128(11): 1728-1746.

[4] [4] PATEL K K, VENKATESAN C, ABDELHALIM H, et al. Genomic approaches to identify and investigate genes associated with atrial fibrillation and heart failure susceptibility[J]. Hum Genomics, 2023, 17(1): 47.

[5] [5] YUAN S, LIN A, HE Q Q, et al. Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes: a two-sample Mendelian randomization study[J]. Int J Cardiol, 2020, 313: 99-104.

[7] [7] KOTALCZYK A, LIP G Y, CALKINS H. The 2020 ESC guidelines on the diagnosis and management of atrial fibrillation[J]. Arrhythm Electrophysiol Rev, 2021, 10(2): 65-67.

[8] [8] MIDDELDORP M E, ARIYARATNAM J P, KAMSANI S H, et al. Hypertension and atrial fibrillation[J]. J Hypertens, 2022, 40(12): 2337-2352.

[10] [10] KIM S H, LIM K R, SEO J H, et al. Higher heart rate variability as a predictor of atrial fibrillation in patients with hypertension[J]. Sci Rep, 2022, 12(1): 3702.

[12] [12] SASANO T, IHARA K, TANAKA T, et al. Risk stratification of atrial fibrillation and stroke using single nucleotide polymorphism and circulating biomarkers[J]. PLoS One, 2023, 18(10): e0292118.

[13] [13] GOETTE A, LENDECKEL U. Atrial cardiomyopathy: pathophysiology and clinical consequences[J]. Cells, 2021, 10(10): 2605.

[14] [14] AJOOLABADY A, NATTEL S, LIP G Y H, et al. Inflammasome signaling in atrial fibrillation: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2022, 79(23): 2349-2366.

[15] [15] LIN K B, FAN F H, CAI M Q, et al. Systemic immune inflammation index and system inflammation response index are potential biomarkers of atrial fibrillation among the patients presenting with ischemic stroke[J]. Eur J Med Res, 2022, 27(1): 106.

[16] [16] KATKAM S K, RAJASEKHAR L, TASNEEM F S D, et al. Synergetic interaction of HLA-DRB1*07 allele and TNF-alpha-863 C/a single nucleotide polymorphism in the susceptibility to systemic lupus erythematosus[J]. Indian J Clin Biochem, 2021, 36(1): 59-66.

[17] [17] SALARI N, MANSOURI K, HOSSEINIAN-FAR A, et al. The effect of polymorphisms (174G>C and 572C>G) on the Interleukin-6 gene in coronary artery disease: a systematic review and meta-analysis[J]. Genes Environ, 2021, 43(1): 1.

[18] [18] WU F, FENG X, WU Y, et al. Interleukin-6 receptor Asp358 A>C polymorphism is associated with postoperative atrial fibrillation[J]. Ann Thorac Surg, 2021, 111(1): 102-108.

[21] [21] LIU Y, WU F, WU Y, et al. Mechanism of IL-6-related spontaneous atrial fibrillation after coronary artery grafting surgery: IL-6 knockout mouse study and human observation[J]. Transl Res, 2021, 233: 16-31.

[22] [22] SEGAN L, CANOVAS R, NANAYAKKARA S, et al. New-onset atrial fibrillation prediction: the HARMS2-AF risk score[J]. Eur Heart J, 2023, 44(36): 3443-3452.

[23] [23] LEE S R, CHOI E K, JUNG J H, et al. Smoking cessation after diagnosis of new-onset atrial fibrillation and the risk of stroke and death[J]. J Clin Med, 2021, 10(11): 2238.